Hong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hong Li has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Cai Li
Department of Pharmacy, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
3 shared publicationsJiahui Wang
Department of Psychiatry, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
3 shared publicationsJun Cheng
Department of Psychiatry, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
3 shared publicationsYitong Liu
Department of Psychiatry, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
3 shared publicationsHaijin Li
Department of Psychiatry The First Affiliated Hospital of Zhengzhou University Zhengzhou China
2 shared publicationsLei Yang
Department of Psychiatry, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 shared publications
Latest Publications
- Open Access
- 29 August 2026
- Published by Springer Nature in BMC Psychiatry
Differential nodal topology in resting-state networks as a potential imaging marker for adolescent bipolar and depressive disorders
- 29 August 2026
- Published by Springer Nature in BMC Psychiatry
Open AccessDifferential nodal topology in resting-state networks as a potential imaging marker for adolescent bipolar and depressive disorders
- Open Access
- 16 May 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Altered NK cell receptor profiles and immune-inflammatory markers in adolescent Major depressive disorder: associations with cognitive impairment
Immune dysregulation and cognitive deficits are increasingly recognized in adolescent major depressive disorder (MDD), yet their interrelationship remains unclear. This study aimed to investigate peripheral immune-inflammatory alterations and natural killer (NK) cell phenotypes, and explore their association with cognitive function in adolescent MDD. Fifty-four first-episode, drug-naïve adolescents with MDD and 33 matched healthy controls (HCs) were enrolled. Group differences in peripheral blood immune-inflammatory indices (NLR, PLR, MLR, SII, SIRI), NK cell surface receptors (HLA-DR, NKp46, NKp30, NKG2A, NKG2C, KIR2DL1, ILT2, CD57), and cognitive function were analyzed, along with their intercorrelations. Compared with HCs, patients with MDD showed lower NEU, NLR, PLR, and SII levels, alongside elevated LYM counts. NK cells exhibited reduced overall proportions but increased expression of HLA-DR, NKp46, NKG2A, and ILT2, with decreased CD57 expression in the MDD group. Significant cognitive impairments were observed in speed of processing, reasoning and problem solving, and social cognition. Exploratory analyses suggested potential links between immune measures and cognitive performance, which require confirmation in larger samples. The observed immune and cognitive alterations warrant further investigation into potential neuroimmune mechanisms in adolescent MDD. This study provides novel insight into potential biomarkers and immunomodulatory targets for early intervention in adolescent MDD. Not applicable.
- 16 May 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Open AccessAltered NK cell receptor profiles and immune-inflammatory markers in adolescent Major depressive disorder: associations with cognitive impairment
Immune dysregulation and cognitive deficits are increasingly recognized in adolescent major depressive disorder (MDD), yet their interrelationship remains unclear. This study aimed to investigate peripheral immune-inflammatory alterations and natural killer (NK) cell phenotypes, and explore their association with cognitive function in adolescent MDD. Fifty-four first-episode, drug-naïve adolescents with MDD and 33 matched healthy controls (HCs) were enrolled. Group differences in peripheral blood immune-inflammatory indices (NLR, PLR, MLR, SII, SIRI), NK cell surface receptors (HLA-DR, NKp46, NKp30, NKG2A, NKG2C, KIR2DL1, ILT2, CD57), and cognitive function were analyzed, along with their intercorrelations. Compared with HCs, patients with MDD showed lower NEU, NLR, PLR, and SII levels, alongside elevated LYM counts. NK cells exhibited reduced overall proportions but increased expression of HLA-DR, NKp46, NKG2A, and ILT2, with decreased CD57 expression in the MDD group. Significant cognitive impairments were observed in speed of processing, reasoning and problem solving, and social cognition. Exploratory analyses suggested potential links between immune measures and cognitive performance, which require confirmation in larger samples. The observed immune and cognitive alterations warrant further investigation into potential neuroimmune mechanisms in adolescent MDD. This study provides novel insight into potential biomarkers and immunomodulatory targets for early intervention in adolescent MDD. Not applicable.
- Open Access
- 19 September 2024
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (9) , e70048
Changes in the medial prefrontal cortex metabolites after 6 months of medication therapy for patients with bipolar disorder: A 1H‐MRS study
Aims: The study aimed to assess brain metabolite differences in the medial prefrontal cortex (mPFC) between acute and euthymic episodes of bipolar disorder (BD) with both mania and depression over a 6‐month medication treatment period.Methods: We utilized 1H‐MRS technology to assess the metabolite levels in 53 individuals with BD (32 in depressive phase, 21 in manic phase) and 34 healthy controls (HCs) at baseline. After 6 months of medication treatment, 40 subjects underwent a follow‐up scan in euthymic state. Metabolite levels, including N‐acetyl aspartate (NAA), glutamate (Glu), and Glutamine (Gln), were measured in the mPFC.Results: Patients experiencing depressive and manic episodes exhibited a notable reduction in NAA/Cr + PCr ratios at baseline compared to healthy controls (p = 0.004; p = 0.006) in baseline, compared with HCs. Over the 6‐month follow‐up period, the manic group displayed a significant decrease in Gln/Cr + PCr compared to the initial acute phase (p = 0.03). No significant alterations were found in depressed group between baseline and follow‐up.Conclusion: This study suggests that NAA/Cr + PCr ratios and Gln/Cr + PCr ratios in the mPFC may be associated with manic and depressive episodes, implicating that Gln and NAA might be useful biomarkers for distinguishing mood phases in BD and elucidating its mechanisms.
- 19 September 2024
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (9) , e70048
Open AccessChanges in the medial prefrontal cortex metabolites after 6 months of medication therapy for patients with bipolar disorder: A 1H‐MRS study
Aims: The study aimed to assess brain metabolite differences in the medial prefrontal cortex (mPFC) between acute and euthymic episodes of bipolar disorder (BD) with both mania and depression over a 6‐month medication treatment period.Methods: We utilized 1H‐MRS technology to assess the metabolite levels in 53 individuals with BD (32 in depressive phase, 21 in manic phase) and 34 healthy controls (HCs) at baseline. After 6 months of medication treatment, 40 subjects underwent a follow‐up scan in euthymic state. Metabolite levels, including N‐acetyl aspartate (NAA), glutamate (Glu), and Glutamine (Gln), were measured in the mPFC.Results: Patients experiencing depressive and manic episodes exhibited a notable reduction in NAA/Cr + PCr ratios at baseline compared to healthy controls (p = 0.004; p = 0.006) in baseline, compared with HCs. Over the 6‐month follow‐up period, the manic group displayed a significant decrease in Gln/Cr + PCr compared to the initial acute phase (p = 0.03). No significant alterations were found in depressed group between baseline and follow‐up.Conclusion: This study suggests that NAA/Cr + PCr ratios and Gln/Cr + PCr ratios in the mPFC may be associated with manic and depressive episodes, implicating that Gln and NAA might be useful biomarkers for distinguishing mood phases in BD and elucidating its mechanisms.
- 29 June 2023
- Published by Elsevier in Journal of Affective Disorders
- Vol. 339, 98-103
Response rate and safety of antidepressants combined with electroconvulsive therapy in adolescent depression: Real-world clinical application
- 29 June 2023
- Published by Elsevier in Journal of Affective Disorders
- Vol. 339, 98-103
Response rate and safety of antidepressants combined with electroconvulsive therapy in adolescent depression: Real-world clinical application
- Open Access
- 17 March 2015
- Published by Springer Nature in BMC Psychiatry
- Vol. 15 (1) , 1-7
Elevated mitochondrial DNA copy number in peripheral blood cells is associated with childhood autism
Several lines of evidence indicate mitochondrial impairment in the pathophysiology of autism. As one of the most common biomarkers for mitochondrial dysfunction, mitochondrial DNA (mtDNA) copy number has also been linked to autism, but the relationship between mtDNA copy number and autism was still obscured. In this study, we performed a case–control study to investigate whether mtDNA copy number in peripheral blood cells is related to patients with autism. Relative mtDNA copy number in peripheral blood cells was measured by using real-time polymerase chain reaction method. The participants in this study included 78 patients with childhood autism and 83 typically developing children. We observed children with autism had significantly elevated relative mtDNA copy number than healthy controls (Beta = −0.173, P = 0.0003). However, there were no significant correlations between mtDNA copy number and clinical features (paternal age, maternal age, age of onset, illness of duration, CARS score and ABC score) in childhood autism. We show that elevated mtDNA copy number in peripheral blood is associated with autism, indicating that there may be mitochondrial dysfunction in children with autism.
- 17 March 2015
- Published by Springer Nature in BMC Psychiatry
- Vol. 15 (1) , 1-7
Open AccessElevated mitochondrial DNA copy number in peripheral blood cells is associated with childhood autism
Several lines of evidence indicate mitochondrial impairment in the pathophysiology of autism. As one of the most common biomarkers for mitochondrial dysfunction, mitochondrial DNA (mtDNA) copy number has also been linked to autism, but the relationship between mtDNA copy number and autism was still obscured. In this study, we performed a case–control study to investigate whether mtDNA copy number in peripheral blood cells is related to patients with autism. Relative mtDNA copy number in peripheral blood cells was measured by using real-time polymerase chain reaction method. The participants in this study included 78 patients with childhood autism and 83 typically developing children. We observed children with autism had significantly elevated relative mtDNA copy number than healthy controls (Beta = −0.173, P = 0.0003). However, there were no significant correlations between mtDNA copy number and clinical features (paternal age, maternal age, age of onset, illness of duration, CARS score and ABC score) in childhood autism. We show that elevated mtDNA copy number in peripheral blood is associated with autism, indicating that there may be mitochondrial dysfunction in children with autism.